Incidence of Candidemia Is Higher in COVID-19 versus Non-COVID-19 Patients, but Not Driven by Intrahospital Transmission
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
There is scarce information on the actual incidence of candidemia in COVID-19 patients. In addition, comparative studies of candidemia episodes in COVID-19 and non-COVID-19 patients are heterogeneous. Here, we assessed the real incidence, epidemiology, and etiology of candidemia in COVID-19 patients, and compared them with those without COVID-19 (2020 vs. 2019 and 2020, respectively). We also genotyped all C. albicans, C. parapsilosis, and C. tropicalis isolates (n = 88), causing candidemia in both groups, providing for the first time a genotypic characterization of isolates gathered in patients with either COVID-19 or non-COVID-19. Incidence of candidemia was higher in patients with COVID-19 than non-COVID-19 (4.73 vs. 0.85 per 1000 admissions; 3.22 vs. 1.14 per 10,000 days of stay). No substantial intergroup differences were found, including mortality. Genotyping proved the presence of a low number of patients involved in clusters, allowing us to rule out rampant patient-to-patient Candida transmission. The four patients, involved in two clusters, had catheter-related candidemia diagnosed in the first COVID-19 wave, which demonstrates breaches in catheter management policies occurring in such an overwhelming situation. In conclusion, the incidence of candidemia in patients with COVID-19 is significantly higher than in those without COVID-19. However, genotyping shows that this increase is not due to uncontrolled intrahospital transmission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In fact, some studies found higher candidemia incidence among patients with COVID-19 infections compared to those without.36–40”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [39]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rawson, T. M., Moore, L. S. P., Zhu, N., Ranganathan, N., Skolimowska, K., Gilchrist, M., Satta, G., Cooke, G., & Holmes, A. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa530 · Cited by 1,662
Garcia-Vidal, C., Sanjuan, G., Moreno-García, E., Puerta-Alcalde, P., Garcia-Pouton, N., Chumbita, M., Fernandez-Pittol, M., Pitart, C., Inciarte, A., Bodro, M., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.07.041 · Cited by 1,022 · cited 2×
“Unfortunately, studies have been mostly addressed to describe bacterial superinfections [4,5] and Coronavirus-Associated Pulmonary Aspergillosis (CAPA) [6–9].”
BackgroundKoehler, P., Bassetti, M., Chakrabarti, A., Chen, S. C. A., Colombo, A. L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R. O., Vinh, D. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30847-1 · Cited by 951
Song, G., Liang, G., & Liu, W. (2020) · Mycopathologia · doi:10.1007/s11046-020-00462-9 · Cited by 644 · cited 1×
“Previous studies in which Candida genotypi g was carried out are limited by th fact t at the number of isolates was low, they ere sourced exclusiv ly from patients w th COVID-19, and they were not designed to address the question of clonal spreading as a driver of hig er candidemia incidenc in COVID-19 patients [30, 1…”
ResultChanges in the epidemiological landscape of invasive candidiasis
Lamoth, F., Lockhart, S. R., Berkow, E. L., & Calandra, T. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx444 · Cited by 547
White, P. L., Dhillon, R., Cordey, A., Hughes, H., Faggian, F., Soni, S., Pandey, M., Whitaker, H., May, A., Morgan, M., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1298 · Cited by 445 · cited 1×
“These data reinforce the importance of optimal catheter management to prevent healthcare-associated infections, preestablished diagnostic algorithms, and stewardship programs under current conditions [23,39].”
BackgroundInvasive fungal diseases during COVID-19: We should be prepared
Gangneux, J.-P., Bougnoux, M.-E., Dannaoui, E., Cornet, M., & Zahar, J. R. (2020) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2020.100971 · Cited by 347
Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis
Koehler, P., Stecher, M., Cornely, O. A., Koehler, D., Vehreschild, M. J. G. T., Bohlius, J., Wisplinghoff, H., & Vehreschild, J. J. (2019) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.04.024 · Cited by 336 · cited 3×
“Thirty-day mortality rate of candidemia in tertiary care hospitals has been reported to be around 38% in Europe [48]; in our cohort, the overall mortality rate was 22% (23/103), increasing to 32% in patients with COVID-19.”
BackgroundInfluentialChowdhary, A., Tarai, B., Singh, A., & Sharma, A. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2611.203504 · Cited by 330 · cited 2×
“In the current pandemic situation, an increase in candidemia by multidrug strains such as Candida auris has been reported in some countries, perhaps due to the difficulties in preserving nosocomial infection control programs [17].”
BackgroundBloodstream infections in critically ill patients with COVID‐19
Giacobbe, D. R., Battaglini, D., Ball, L., Brunetti, I., Bruzzone, B., Codda, G., Crea, F., De Maria, A., Dentone, C., Di Biagio, A., et al. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13319 · Cited by 302 · cited 2×
“I ( rti l rl t ri l) r f t t fre e t types of infection in this setting, with a reported incidence rate of 47 episodes (95% confide ce interval (CI) 35–63) per 1000 patient-days at risk [33].”
Background
Research works printed but not linked: 1
- Mastrangelo, 2020, Candidemia in COVID-19 patients: Incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls, Clin. Infect. Dis., 30, ciaa1594
Cited by
Candida albicans and Candida glabrata : global priority pathogens
Katsipoulaki, M., Stappers, M. H. T., Malavia-Jones, D., Brunke, S., Hube, B., & Gow, N. A. R. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00021-23 · Cited by 180
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Candidiasis and Other Emerging Yeasts
Sharma, M., & Chakrabarti, A. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00455-3 · Cited by 123
“parapsilosis to fluconazole and voriconazole during COVID-19 pandemic [79, 80].”
Candida parapsilosis complex in the clinical setting
Govrins, M. A., & Lass‐Flörl, C. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00961-8 · Cited by 94
“Firstly, COVID-19-associated candidiasis cases in patients who are critically ill increased significantly 41,42 , with candidaemia occurring at a two to ten times higher rate than that reported in historical populations without COVID-19 (ref.”
BackgroundFluconazole-resistant Candida parapsilosis: A new emerging threat in the fungi arena
Escribano, P., & Guinea, J. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.1010782 · Cited by 74
“Inour hospital,whereas the incidence of candidaemiawas higher in patients with COVID-19 than without, genotyping demonstrated that the increasewasnot due touncontrolled intra-hospital patientto-patient transmission (Machado et al., 2022).”
BackgroundSelf-citationCOVID-19-associated candidiasis and the emerging concern of Candida auris infections
Tsai, C.-S., Lee, S. S., Chen, W.-C., Tseng, C.-H., Lee, N., Chen, P., Li, M.-C., Syue, L.-S., Lo, C.-L., Ko, W., et al. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.12.002 · Cited by 68
The rise of Candida auris: from unique traits to co-infection potential
Egger, N. B., Kainz, K., Schulze, A., Bauer, M. A., Madeo, F., & Carmona‐Gutiérrez, D. (2022) · Microbial Cell · doi:10.15698/mic2022.08.782 · Cited by 53
Papadimitriou-Olivgeris, M., Kolonitsiou, F., Kefala, S., Spiliopoulou, A., Aretha, D., Bartzavali, C., Siapika, A., Marangos, M., & Fligou, F. (2022) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2022.102353 · Cited by 39
Díaz-García, J., Gómez, A., Machado, M., Alcalá, L., Reigadas, E., Sánchez-Carrillo, C., Pérez-Ayala, A., Gómez-García De La Pedrosa, E., González-Romo, F., Cuétara, M. S., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac288 · Cited by 35
Self-citationCOVID-19-Associated Fungal Infections: An Urgent Need for Alternative Therapeutic Approach?
Domán, M., & Bànyai, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.919501 · Cited by 29
Yeast Bloodstream Infections in the COVID-19 Patient: A Multicenter Italian Study (FiCoV Study)
Prigitano, A., Blasi, E., Calabrò, M., Cavanna, C., Cornetta, M., Farina, C., Grancini, A., Innocenti, P., Cascio, G. L., Nicola, L., et al. (2023) · Journal of Fungi · doi:10.3390/jof9020277 · Cited by 22
Mortality of Patients With Candidemia and COVID-19: A Systematic Review With Meta-analysis
Colaneri, M., Giusti, E. M., Genovese, C., Galli, L., Lombardi, A., & Gori, A. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad358 · Cited by 24
“Patients with coronavirus disease 2019 (COVID-19) have multiple reasons to be at higher risk for candidemia, such as iatrogenic immunosuppression [8], other bloodstream infections mainly due to bacteria and their associated high rates of antibiotic use [9], and indwelling vascular catheters [10].”
BackgroundDíaz-García, J., Gómez, A., Machado, M., Alcalá, L., Reigadas, E., Sánchez‐Carrillo, C., Pérez‐Ayala, A., de la Pedrosa, E. G., González‐Romo, F., Cuétara, M. S., et al. (2022) · Journal of Fungi · doi:10.3390/jof8111228 · Cited by 19
“We detected an increase in the incidence of candidaemia during 2020 and 2021 in some participating hospitals, which is in line with previous reports conducted during the COVID-19 pandemic [9–14].”
Self-citationFungal Infections in the ICU during the COVID-19 Pandemic in Mexico
Román-Montes, C. M., Bojorges-Aguilar, S., Corral-Herrera, E. A., Rangel‐Cordero, A., Diaz‐Lomelí, P., Sánchez, A. C., Martínez-Guerra, B. A., Rajme‐López, S., Tamez-Torres, K. M., Martínez‐Gamboa, R. A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9050583 · Cited by 17
“Moreover, what was evidenced was the lack of catheter care measures due to the high prevalence of catheter-related infection; this finding, what we believe, is due to an associated factor [35].”
BackgroundSrisurapanont, K., Lerttiendamrong, B., Meejun, T., Thanakitcharu, J., Manothummetha, K., Thongkam, A., Chuleerarux, N., Sanguankeo, A., Li, L. X., Leksuwankun, S., et al. (2024) · Mycoses · doi:10.1111/myc.13798 · Cited by 18
“A total of 43 studies reported the prevalence of CAC among 54,485 patients with COVID-19 in ICUs [12, 19–21, 23, 26, 28, 40, 42–45, 48–51, 53, 54, 56, 58, 61, 62, 67, 69, 74, 75, 77, 78, 81, 85, 86, 89, 91, 93, 94, 96–98, 100, 103, 104, 106, 108].”
InfluentialCandida in COVID-19: Gut-Lung Axis, Dysbiosis, and Infections
Kordalewska, M., & Perlin, D. S. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00476-y · Cited by 17
“However, results of Candida spp. clinical isolates genotyping revealed that such an increase was not characterized by an uncontrolled nosocomial transmission [60, 68, 69 • ], except for the spread of Candida auris (see the next section).”
Occurrence of Candidemia in Patients with COVID-19 Admitted to Five ICUs in France
Blaize, M., Raoelina, A., Kornblum, D., Kamus, L., Lampros, A., Berger, M., Demeret, S., Constantin, J., Monsel, A., Mayaux, J., et al. (2022) · Journal of Fungi · doi:10.3390/jof8070678 · Cited by 16
When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection
Pruthi, H. S. (2022) · Current Clinical Microbiology Reports · doi:10.1007/s40588-022-00184-0 · Cited by 13
Leitl, C. J., Stoll, S. E., Wetsch, W. A., Kammerer, T., Mathes, A., Böttiger, B. W., Seifert, H., & Dusse, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041466 · Cited by 11
Díaz-García, J., Mesquida, A., Machado, M., Sánchez‐Carrillo, C., Muñóz, P., Escribano, P., & Guinea, J. (2023) · Medical Mycology · doi:10.1093/mmy/myad072 · Cited by 11
Self-citationUnresolved issues in the diagnosis of catheter related candidemia: A position paper
Soriano-Martín, A., Muñóz, P., García‐Rodríguez, J., Cantón, R., Vena, A., Bassetti, M., & Bouza, E. (2023) · Revista Española de Quimioterapia · doi:10.37201/req/112.2023 · Cited by 11
“Data from one of our institutions show an incidence of 4.73 versus 0.85 episodes per 1,000 admissions-year in patients with and without COVID-19 respectively [31].”
BackgroundInfluentialSelf-citationAydın, S., Mert, A., Yılmaz, M., Maslamani, M. A. R. S. A., Rahimi, B. A., Ayoade, F., El‐Kholy, A., Belitova, M., Şengel, B. E., Jalal, S., et al. (2024) · Mycoses · doi:10.1111/myc.13687 · Cited by 12
Zakhem, A. E., Mahmoud, O. K., Zakhour, J., Nahhal, S. B., Ghawi, N. E., Omran, N., Sheikh, W. G. E., Tamim, H., & Kanj, S. S. (2023) · Journal of Fungi · doi:10.3390/jof9070769 · Cited by 12
Candidemia in critically ill COVID-19 patients: Risk factors and impact on mortality
Kazancıoğlu, S., Bodur, H., Mumcuoğlu, İ., Baştuğ, A., Özbay, B. O., Aydos, Ö., & Dinç, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28033 · Cited by 10
“Increased candidemia incidence was previously reported in COVID-19 and non-COVID-19 patients during the pandemic [8 – 10].”
BackgroundLin, G.-L., Chang, P.-H., Lee, I., Chen, Y., & Lee, C. (2024) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2024.07.014 · Cited by 9
Soriano-Martín, A., Escribano, P., Machado, M., Guinea, J., Reigadas, E., García-Clemente, P., Bouza, E., & Muñóz, P. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf359 · Cited by 8
“An exception in our study is 2020, the year of the COVID-19 pandemic, when the incidence of C. albicans and C. parapsilosis increased and decreased, respectively, in our institution [43].”
Self-citationInvasive fungal disease in COVID-19 patients: a single-center prospective observational study
Adžić‐Vukičević, T., Mladenovic, M., Jovanović, S., Soldatović, I., & Radovanović-Spurnić, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1084666 · Cited by 13
“3%) patients who were either admitted to ICU or were septic shock patients, as reported in a recently published study (16).”
BackgroundResultKozlova, O. P., Burygina, E. V., Khostelidi, S. N., Витальевна, Ш. О., Saturnov, A., Gusev, D. A., Rysev, A. V., Zavrazhnov, A., Vashukova, M. A., Pichugina, G., et al. (2023) · Journal of Fungi · doi:10.3390/jof9090927 · Cited by 8
“According to our study, the presence of CVC for more than 10 days significantly increased the risk of developing IC (OR = 70 [15–309]) in patients with COVID-19 and occurred in 98% of our patients, which was comparable with the data of international studies (74–94%) [5,9,19].”
ResultKaradağ, F. Y., Öztürk-Engin, D., Buber, A. A., Görmüş, T., Arslan, E., Çetin, A. Ş., TEKİN, S., Sayan, İ., Bayri, C., Odabaşı, H., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10688-x · Cited by 8
“A study comparing candidemia patients with and without COVID-19 infection reported higher rates of septic shock, total parenteral nutrition, central venous catheter use, corticosteroid therapy, and previous ICU admission in COVID-19 patients [18].”
InfluentialInvasive Candidiasis Coinfection in Patients with Severe COVID-19 Disease: Scoping Review
Valencia-Ledezma, O. E., Reyes-Montes, M. D. R., Acosta‐Altamirano, G., León, M. G. F.-D., García-Salazar, E., Duarte-Escalante, E., Santiago-Abundio, J., Miguel, Z. G., Hernández, M. D. L. G., Martínez-Quezada, R., et al. (2025) · Pathogens · doi:10.3390/pathogens14050466 · Cited by 8
“Several studies had described the incidence of candidiasis and mortality rates in patients with COVID-19 as higher in relation to patients without said disease [3–7].”
InfluentialOral Myco- and Bacteriobiota and Yeast Infections in Mechanically Ventilated COVID-19 Patients
Gregorczyk‐Maga, I., Kania, M., Sulik‐Tyszka, B., Namysł, M., Sepioło, A., Romaniszyn, D., Jachowicz-Matczak, E., & Wójkowska‐Mach, J. (2023) · Microorganisms · doi:10.3390/microorganisms11061442 · Cited by 6
Accelerated Increase in Candida auris Bloodstream Infections during COVID-19 Pandemic, South Africa
Ismail, H., Perovic, O., Mpembe, R. S., Lowman, W., Govind, C., Ekermans, P., Jassat, W., Welch, R., & Govender, N. P. (2026) · Emerging infectious diseases · doi:10.3201/eid3204.251407 · Cited by 5
Deckers, C., Bélik, F., Khourssaji, M., Plum, P.-E., Ausselet, N., Bulpa, P., Sonet, A., Bihin, B., Huang, T., Denis, O., et al. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116493 · Cited by 6
Shin, S. U., Bae, S., Cho, D. J., Lee, A. K., Jeong, H. S., Hwang, S., Kim, S., Kim, M., Kim, S. E., Kim, U. J., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10373-5 · Cited by 5
Leite, D. P. (2023) · Virology & Immunology Journal · doi:10.23880/vij-16000331 · Cited by 10
Simonetti, O., Zerbato, V., Sincovich, S., Cosimi, L., Zorat, F., Costantino, V., Santolo, M. D., Busetti, M., Bella, S. D., Principe, L., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12040691 · Cited by 5
“, the administration of tocilizumab or high doses of corticosteroids), and the increased use of antibiotics and their effects on the gut microbiome [5].”
BackgroundImoto, W., Ihara, Y., Bito, T., Kawai, R., Namikawa, H., Shibata, W., Kaneko, Y., Shintani, A., & Kakeya, H. (2025) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2025.102689 · Cited by 4
Pienthong, T., Visuttichaikit, S., Apisarnthanarak, P., Jantarathaneewat, K., Weber, D. J., & Apisarnthanarak, A. (2023) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.354 · Cited by 4
Hao, S., Zhou, C., Wei, Y., Wang, Y., Pan, J., Song, J., & Zhong, M. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00076-25 · Cited by 3
Report of the First Case of Candida auris Identified in Jordan
Wadi, J., Ghanem, R. A., Sayyouh, O., Al-Jammal, D., Said, M. M., Nasrat, S., El-Shokry, M., Gazo, M., & Osman, T. S. (2023) · Microbiology Research · doi:10.3390/microbiolres14040107 · Cited by 4
Oñate-Gutiérrez, J. M., Álvarez, C., Cañadas-Aragón, C. P., & Vergara, H. (2026) · Journal of Fungi · doi:10.3390/jof12040278 · Cited by 3
“No-tably, ICU candidemia prevalence during the pandemic was estimated to be approximately 10 times higher than in the pre-pandemic era [15].”
EREN, E. E., Iosifidis, Ε., Sav, H., Çelik, İ., Mouloudi, E. K., Pyrpasopoulou, A., Zarras, C., & Roilides, E. (2026) · Mycopathologia · doi:10.1007/s11046-026-01086-1 · Cited by 2
“Araujo JM. et al., reported that in 2020, the incidence of candidemia per 1000 patient-days in Brazil increased by ) [5).”
Risk analysis of candidemia and its effect on mortality in COVID 19 and non COVID 19 patients
Özmerdiven, G. E., İrvem, A., & Şahin, A. S. (2024) · Iranian Journal of Microbiology · doi:10.18502/ijm.v16i2.15357 · Cited by 3
“In this study, as in similar studies, no significant difference was observed in terms of age and gender (9, 11).”
BackgroundResultInfluentialGreen Fungus Challenges in Post-COVID Health Landscape
Jeha, J., Sudha, S., B, G. N., & Benitta Sherine, S. (2024) · Journal of Angiotherapy · doi:10.25163/angiotherapy.829463 · Cited by 2
Candida spp.: the burden of a microorganism in a microbiology department
Soriano-Martín, A., Alonso, R., Machado, M., Reigadas, E., Muñóz, P., & Bouza, E. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03860-23 · Cited by 1
“Few studies have assessed the workload associated with the identification of specific microorganisms (18–24), although there are some reports describing the laboratory workload related to Streptococcus pneumoniae and Aspergillus fumigatus (25, 26).”
BackgroundSelf-citationCurrent Issues in Fungal Infections and COVID-19
Fernández‐Cruz, A., & Magira, E. E. (2022) · Journal of Fungi · doi:10.3390/jof8111115 · Cited by 1
Suplemento do II Congresso de Infectologia e Medicina tropical do UNIBH
(2022) · Revista Médica de Minas Gerais · doi:10.5935/2238-3182.v32supl.9
Felix, G. N. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-16062023-113452 · Cited by 2
Characterization of COVID ‐19‐Associated Candidemia Among Burn Patients
Salimi, M., Javidnia, J., Moslemi, A., Abastabar, M., Mobayen, M., Rahimzadeh, G., Tirabadi, N. M., Nouranibaladezaei, S., Asghari, H., Sobouti, B., et al. (2025) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.70031
EPIDEMIOLOGIA DA CANDIDEMIA ASSOCIADA À COVID-19
Barros, C., Neves, M. S. D. O., Campos, J. V., & Cavalcanti, D. R. (2025) · Revista Interfaces Saúde Humanas e Tecnologia · doi:10.16891/2317-434x.v13.e3.a2025.id2775
Şahin, S., Bombacı, E., Kaya, B., & Tekol, S. D. (2025) · IJID Regions · doi:10.1016/j.ijregi.2025.100807
“A report from Spain, one of the world’s worst-hit countries by the pandemic, found a higher incidence of candidemia in patients with COVID-19 (4.73 vs 0.85 per 1000 admissions) [ 9 ].”
InfluentialNamysł, M., Skóra, M., Pomorska-Wesołowska, M., Romanik, M. K., Kwapniewska, W. Ś. –., Serwacki, P., Pawłowska, I., Olechowska‐Jarząb, A., & Wójkowska‐Mach, J. (2026) · Journal of Fungi · doi:10.3390/jof12030212
“…2021—many centers reported increased candidemia incidence and altered species distribution driven by prolonged ICU stays, extensive use of broad-spectrum antibiotics, corticosteroids, immunomodulatory therapies, and high device burden (mechanical ventilation, central venous catheters) [29,42–44].”
Kaya, G., Küçük, H. İ., Erbay, E. Y., Solmaz, S., Oskay, M., & Han, R. (2026) · Mantar dergisi · doi:10.30708/mantar.1912728
Doruk, B. Ç., & Uğuz, M. Z. (2026) · Antibiotics · doi:10.3390/antibiotics15111083
Metadata
- Authors
- Machado, M., Estévez, A., Sánchez-Carrillo, C., Guinea, J., Escribano, P., Alonso, R., Valerio, M., Padilla, B., Bouza, E., & Muñoz, P.
- Affiliations
- Hospital General Universitario Gregorio Marañón (ES)
- Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Machado, Marina
- Estévez, Agustín
- ORCID
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2022-03-16
- Volume
- 8
- Issue
- 3
- Pages
- 305
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC8950429
- OpenAlex
- W4221131994
- Cited by
- 53
- References
- 50
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 11 · 2023: 18 · 2022: 11
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Docta Complutense (Universidad Complutense de Madrid) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Instituto de Salud Carlos III (PI18/01155, PI19/00074, PI20/00575)
- European Regional Development Fund (ERDF) (N/A)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, COVID-19 pandemic, Candida albicans, Candida parapsilosis, Candida tropicalis, candidemia incidence, genotyping, catheter-related candidemia, central venous catheters, infection clusters, mortality
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.